|Videos|May 19, 2022
Choosing Therapies for Patients with Advanced Renal Cell Carcinoma
Author(s)Tom Powles, MBBS, MRCP, MD, Brian Shimkus, MD
A physician explains why he doesn’t believe there is a “typical” patient and why advanced RCC therapies must be tailored to each case.
Advertisement
Episodes in this series
Advertisement
Related to this article
Black women die from breast cancer at rates 40% higher than white women — and are still missing from the trials that could help. Dr. Coral Omene on why.
A bispecific in biliary tract cancer, dostarlimab organ preservation in rectal cancer, and KRAS G12D data in pancreatic cancer stood out at ESMO 2026.
The European Commission approved adjuvant T-DXd for HER2-positive early breast cancer with residual invasive disease based on DESTINY-Breast05 data.
Dirk Schadendorf, MD, reviewed final STARBOARD data for encorafenib, binimetinib, and pembrolizumab in first-line BRAF V600–mutant melanoma.
In a phase 2 trial, orelabrutinib plus sintilimab yielded a 60.7% overall response rate in relapsed/refractory primary CNS lymphoma.
Presentations at ESMO Congress 2026 detailed how surgery, radiation oncology, and supportive care can contribute to the treatment of patients with NSCLC.
Matthew Lee, MD, discusses the first clinical data for BG-C477, a CEACAM5-targeting ADC, in advanced NSCLC.
Jan Kitajewski, PhD, explains how Notch inhibitors may sustain specialized tumor blood vessels that deliver immune cells and boost immuno-oncology.
Advertisement
Advertisement
Trending on CancerNetwork
1
Prior Regimen Did Not Affect Daraxonrasib Benefit in Pretreated Pancreatic Cancer
2
Petosemtamab/Pembrolizumab Improves OS in First-Line PD-L1–Positive HNSCC
3
Sacituzumab Govitecan PFS Benefit Holds Across Subgroups in Untreated mTNBC
4
Can a Selinexor Quadruplet Treat Myeloma After T-Cell Redirecting Therapy?
5